(FM) Oncología
Departamento académico
![Foto de (FM) Oncología](/img/uploaded/1575D5546D141A10EB89AE669C8B8533.jpg)
![Foto de Christie Hospital NHS Foundation Trust](/img/noimage_org.png)
Christie Hospital NHS Foundation Trust
Mánchester, Reino UnidoPublicaciones en colaboración con investigadores/as de Christie Hospital NHS Foundation Trust (17)
2024
-
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study
Cancer
-
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma
Nature Cancer
2023
-
Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Nature, Vol. 616, Núm. 7957, pp. 563-573
-
Body composition and lung cancer-associated cachexia in TRACERx
Nature Medicine, Vol. 29, Núm. 4, pp. 846-858
-
Evolutionary characterization of lung adenocarcinoma morphology in TRACERx
Nature Medicine
-
Genomic–transcriptomic evolution in lung cancer and metastasis
Nature, Vol. 616, Núm. 7957, pp. 543-552
-
Lung adenocarcinoma promotion by air pollutants
Nature, Vol. 616, Núm. 7955, pp. 159-167
-
The evolution of lung cancer and impact of subclonal selection in TRACERx
Nature, Vol. 616, Núm. 7957, pp. 525-533
-
The evolution of non-small cell lung cancer metastases in TRACERx
Nature, Vol. 616, Núm. 7957, pp. 534-542
-
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Nature, Vol. 616, Núm. 7957, pp. 553-562
2022
-
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
Nature Cancer, Vol. 3, Núm. 6, pp. 696-709
-
Current practice in proton therapy delivery in adult cancer patients across Europe
Radiotherapy and Oncology, Vol. 167, pp. 7-13
-
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268
-
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
Nature medicine, Vol. 28, Núm. 4, pp. 752-765
2021
2020
-
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059
2019
-
Clinical presentation, diagnosis and staging of cholangiocarcinoma
Liver International, Vol. 39, Núm. S1, pp. 98-107